Roivant Sciences Ltd. (ROIV): Net Income

Annual figures by period end, from SEC filings.

-$299.77M

Year ended 2026-03-31

-$266.25M

Trailing 12 months to 2026-06-30

2021-03-31 Net Income (USD) 2026-03-31

Period ended	Net Income	Change YoY	Source filing
2026-03-31	-$299.77M	n/m	2026-05-20, From 2025-04-01
2025-03-31	-$171.98M	n/m	2026-05-20, From 2024-04-01
2024-03-31	$4.35B	n/m	2026-05-20, From 2023-04-01
2023-03-31	-$1.01B	n/m	2025-05-29, From 2022-04-01
2022-03-31	-$845.26M	n/m	2023-06-28, From 2021-04-01
2021-03-31	-$809.23M	n/a	2022-06-28, From 2020-04-01

Net Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
Roivant Sciences Ltd. (ROIV)	2026-03-31	-$299.77M	n/m
Coya Therapeutics, Inc. (COYA)	2025-12-31	-$21.23M	n/m
Aclaris Therapeutics, Inc. (ACRS)	2025-12-31	-$64.92M	n/m
Bolt Biotherapeutics, Inc. (BOLT)	2025-12-31	-$33.38M	n/m
Adagene Inc. (ADAG)	2025-12-31	-$17.61M	n/m
BioAge Labs, Inc. (BIOA)	2025-12-31	-$80.61M	n/m
Xenon Pharmaceuticals Inc. (XENE)	2025-12-31	-$345.91M	n/m
International Stem Cell Corp (ISCO)	2025-12-31	-$418.0K	n/m
Ovid Therapeutics Inc. (OVID)	2025-12-31	-$17.41M	n/m

Compare ROIV, COYA, ACRS, BOLT side by side · Screen every company in Pharmaceutical Preparations ↗